The raised guidance and accelerating HEPZATO volume growth (72% YoY) suggest strong commercial momentum. Watch for continued center expansion and the DELUMA Phase 2 breast cancer trial enrollment updates. The activist presence (9.9% stake) may push for further operational or strategic initiatives.
Drug in focus
DCTH drug pipeline →HEPZATO KIT
▲ Bullish Named in this 8-K- Impact
- Phase
- Approved (FDA)
- Time to market
- Already on the market. FDA-approved August 2023, currently generating commercial revenue.
- Next catalyst
- None dated
What to watchWith no binary FDA catalyst ahead, the stock's near-term direction hinges on commercial execution: watch Q4 2026 earnings (expected early 2027) for continued HEPZATO KIT revenue growth and treatment center expansion. The Phase 2 breast cancer trial is an important long-term value driver but is unlikely to produce pivotal data within 12 months. The stock's 52-week high near $22.32 and strong institutional accumulation suggest the market is already pricing in the current growth trajectory.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 9 $20.27entry
- T+1 · 7d ago −0.84%α −0.47% · $20.10
- T+5 · 20h ago −1.97%α −0.28% · $19.87
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Delcath Systems reported Q3 2026 revenue of $35.1M (vs. $25.8M consensus) and GAAP EPS of $0.17 (vs. $-0.08 consensus), a strong beat. The company raised its full-year 2026 revenue guidance to $115M-$117M, reflecting at least 41% HEPZATO volume growth over 2025. The activist investor (Rosalind Advisors, 9.9% stake) filed an amended 13D 21 days prior, adding pressure for continued execution.
Key Financial Metrics
Key Facts
- Q3 2026 total revenue $35.1M, up 71% from $20.6M in Q3 2025
- GAAP diluted EPS $0.17 vs. consensus estimate of $-0.08
- HEPZATO KIT revenue $32.7M, up 69% from $19.3M in Q3 2025
- Full-year 2026 revenue guidance raised to $115M-$117M from prior at least $100M
- Gross margin improved to 89% from 87% in Q3 2025
- Net income $7.0M vs. $0.8M in Q3 2025; positive adjusted EBITDA $11.5M
- Cash and investments $104.3M, no debt
- 33 active treatment centers vs. 29 in Q1 2026; HEPZATO volume grew ~72% YoY
- Activist Rosalind Advisors holds 9.9% stake (SC 13D/A filed Oct 19, 2026)
Financial Impact
Revenue beat consensus by 36% ($35.1M vs. $25.8M); EPS beat consensus by $0.25; guidance raised by $15M-$17M at midpoint
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| HEPZATO KIT (U.S.) | $32.7M | +69.4% |
| CHEMOSAT (Europe) | $2.4M | +84.6% |
Risk Factors
- Dependence on HEPZATO KIT adoption and treatment center expansion
- Clinical trial costs (R&D $11.0M, up 38% YoY) may pressure margins
- Competition from other liver-directed therapies
- Regulatory and reimbursement risks for HEPZATO KIT
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-071894 |
| Document: dcth-20261109.htm | 0001628280-26-071894 |
| Document: 0001628280-26-071894-index-headers.html | 0001628280-26-071894 |
| Document: 0001628280-26-071894-index.html | 0001628280-26-071894 |
| Document: 0001628280-26-071894.txt | 0001628280-26-071894 |
| 8-K Data (Synthetic) | 0001628280-26-071894 |
Track record
12 reports on DCTH
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.22% at T+60 after the Feb 26, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $21.38 Now $19.87 −7.06% settles Feb 10
- Nov 9, 20267d ago 8-K Bullish 6/10 Viewing Entry $20.27 Now $19.87 −1.97% settles Feb 5
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $14.82 Now $19.87 +34.08% settles Feb 2
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $14.86 Now $19.87 +33.71% settles Jan 26
- Oct 19, 202628d ago SC 13D/A Neutral 4/10 Entry $14.37 Now $19.87 +38.27% settles Jan 14
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $11.77 to $16.48 Now $19.87 +68.89% ▲ +40.08% +35.68% vs SPY
- May 14, 202626w ago 8-K Neutral 3/10 Entry $11.46 to $16.67 Now $19.87 +73.39% ▲ +45.46% +41.87% vs SPY
- May 7, 202627w ago 8-K Neutral 5/10 Entry $11.24 to $13.04 Now $19.87 +76.78% ▲ +16.01% +12.18% vs SPY
- Apr 2, 202632w ago DEFA14A Neutral 3/10 Entry $9.63 to $12.59 Now $19.87 +106.33% ▲ +30.74% +16.58% vs SPY
- Mar 2, 202637w ago Insider Cluster Bullish 6/10 Entry $8.93 to $10.83 Now $19.87 +122.51% ▲ +21.28% +11.95% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers